Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT04728581
Starting soon Not applicable

Improving Sleep After TKA Using Mirtazapine and Quetiapine

NCT04728581 · tracked via the Priya Life Science Netherlands tracker
Sponsor
St. Anna Ziekenhuis, Geldrop, Netherlands
Phase
Not applicable
Started
2024-01-01
Last updated
2023-06-02

Condition(s) studied

Osteo Arthritis KneeInsomnia

Investigational drug(s) / intervention(s)

Mirtazapine →Quetiapine →Placebo

Mirtazapine: Use of 3.75mg mirtazapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 7.5mg mirtazapine.

Quetiapine: Use of 3.125mg quetiapine before lights-out during first 2 weeks after TKA surgery. With insufficient effect on sleep, patients are allowed to increase medication to 6.25mg mirtazapine.

Placebo: a gelatinous capsule without an active ingredient

Study summary

Use of mirtazapine and quetiapine for improvement of sleep quality after TKA

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Indication for TKA Exclusion Criteria: * use of benzodiazepines * use of anti-depressants * use of oxycodone * patients diagnosed with obstructive sleep apnea syndrome, severe respiratory insufficiency, or myasthenia * a known hypersensitivity to mirtazapine, quetiapine and/or related to the gelatinous (placebo) capsule * insufficient understanding of the Dutch language.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Knowledge Center for Orthopedic Surgery, St. Anna hospital Geldrop Netherlands
St. Anna hospital Geldrop Netherlands

On this site

📄 Seroquel (quetiapine) drug profile →

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04728581 on ClinicalTrials.gov ↗ ← All trials in the Netherlands